Atorvastatin protects endothelial colony‑forming cells against H2O2‑induced oxidative damage by regulating the expression of annexin A2

Li,Da‑Wei; Li,Ji‑Hua; Wang,Ying‑Di; Li,Guang‑Ren

doi:10.3892/mmr.2015.4440

Atorvastatin protects endothelial colony‑forming cells against H2O2‑induced oxidative damage by regulating the expression of annexin A2

Authors:
- Da‑Wei Li
- Ji‑Hua Li
- Ying‑Di Wang
- Guang‑Ren Li
View Affiliations

Affiliations: Department of Neurology, Affiliated Hospital of Beihua University, Jilin, Jilin 132000, P.R. China, Department of Ultrasonography, The Third Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Urinary Surgery, The Tumor Hospital of Jilin, Changchun, Jilin 130012, P.R. China, Department of Neurology, The Third Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
Published online on: October 13, 2015 https://doi.org/10.3892/mmr.2015.4440
Pages: 7941-7948
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endothelial dysfunction and injury are central events in the pathogenesis of ischemic vascular disorders. Endothelial progenitor cells (EPCs) are mobilized from the bone marrow into the peripheral circulation, where they locate to sites of injured endothelium and are involved in endothelial repair and vascular regeneration. During these processes, EPCs are exposed to oxidative stress, a crucial pathological condition, which occurs during vascular injury and limits the efficacy of EPCs in the repair of injured endothelium. Statins are effective inhibitors of 3‑hydroxy‑3‑methylglutaryl coenzyme A reductase, and are commonly used to manage and prevent ischemic vascular disease by reducing plasma cholesterol levels. In addition to lowering cholesterol, statins have also been reported to exert pleiotropic actions, including anti‑inflammatory and anti‑oxidative activities. The present study aimed to investigate the ability of atorvastatin to protect endothelial colony‑forming cells (ECFCs), a homogeneous subtype of EPCs, from hydrogen peroxide (H2O2)‑induced oxidative damage, and to determine the mechanism underlying this protective action. MTT assay, acridine orange/ethidium bromide staining, reactive oxygen species assay, western blot analysis and tube formation assay were employed. The results demonstrated that H2O2 induced cell death and decreased the tube‑forming ability of the ECFCs, in a concentration‑dependent manner; however, these effects were partially attenuated following administration of atorvastatin. The reversion of the quantitative and qualitative impairment of the H2O2‑treated ECFCs appeared to be mediated by the regulation of annexin A2, as the expression levels of annexin A2 were decreased following treatment with H2O2 and increased following treatment with atorvastatin. These results indicated that annexin A2 may be involved in the H2O2‑induced damage of ECFCs, and in the protective activities of atorvastatin in response to oxidative stress.

View Figures

View References

1	Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G and Nishigaki I: The vascular endothelium and human diseases. Int J Biol Sci. 9:1057–1069. 2013. View Article : Google Scholar : PubMed/NCBI
2	Risau W: Mechanisms of angiogenesis. Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI
3	Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G and Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:964–967. 1997. View Article : Google Scholar : PubMed/NCBI
4	Kässmeyer S, Plendl J, Custodis P and Bahramsoltani M: New insights in vascular development: Vasculogenesis and endothelial progenitor cells. Anat Histol Embryol. 38:1–11. 2009. View Article : Google Scholar
5	Huang L, Hou D, Thompson MA, Baysden SE, Shelley WC, Ingram DA, March KL and Yoder MC: Acute myocardial infarction in swine rapidly and selectively releases highly proliferative endothelial colony forming cells (ECFCs) into circulation. Cell Transplant. 16:887–897. 2007. View Article : Google Scholar
6	Lee JH, Lee SH, Yoo SY, Asahara T and Kwon SM: CD34 hybrid cells promote endothelial colony-forming cell bioactivity and therapeutic potential for ischemic diseases. Arterioscler Thromb Vasc Biol. 33:1622–1634. 2013. View Article : Google Scholar : PubMed/NCBI
7	Schwarz TM, Leicht SF, Radic T, Rodriguez-Araboalaza I, Hermann PC, Berger F, Saif J, Böcker W, Ellwart JW, Aicher A and Heeschen C: Vascular incorporation of endothelial colony-forming cells is essential for functional recovery of murine ischemic tissue following cell therapy. Arterioscler Thromb Vasc Biol. 32:e13–e21. 2012. View Article : Google Scholar
8	Rehman J, Li J, Orschell CM and March KL: Peripheral blood 'endothelial progenitor cells' are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 107:1164–1169. 2003. View Article : Google Scholar : PubMed/NCBI
9	Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT and Ingram DA: Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 109:1801–1809. 2007. View Article : Google Scholar
10	Melero-Martin JM, Khan ZA, Picard A, Wu X, Paruchuri S and Bischoff J: In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood. 109:4761–4768. 2007. View Article : Google Scholar : PubMed/NCBI
11	Lin Y, Weisdorf DJ, Solovey A and Hebbel RP: Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 105:71–77. 2000. View Article : Google Scholar : PubMed/NCBI
12	Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM and Park YB: Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 24:288–293. 2004. View Article : Google Scholar
13	Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM and Asahara T: Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 107:1322–1328. 2003. View Article : Google Scholar : PubMed/NCBI
14	Rodriguez AL, Wojcik BM, Wrobleski SK, Myers DD Jr, Wakefield TW and Diaz JA: Statins, inflammation and deep vein thrombosis: A systematic review. J Thromb Thrombolysis. 33:371–382. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kopterides P and Falagas ME: Statins for sepsis: A critical and updated review. Clin Microbiol Infect. 15:325–334. 2009. View Article : Google Scholar : PubMed/NCBI
16	Kuoppala J, Lamminpää A and Pukkala E: Statins and cancer: A systematic review and meta-analysis. Eur J Cancer. 44:2122–2132. 2008. View Article : Google Scholar : PubMed/NCBI
17	McFarland AJ, Anoopkumar-Dukie S, Arora DS, Grant GD, McDermott CM, Perkins AV and Davey AK: Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci. 15:20607–20637. 2014. View Article : Google Scholar : PubMed/NCBI
18	Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V and Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 364:685–696. 2004. View Article : Google Scholar : PubMed/NCBI
19	Cahoon WD Jr and Crouch MA: Preprocedural statin therapy in percutaneous coronary intervention. Ann Pharmacother. 41:1687–1693. 2007. View Article : Google Scholar : PubMed/NCBI
20	Dilaveris P, Giannopoulos G, Riga M, Synetos A and Stefanadis C: Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol. 5:227–237. 2007. View Article : Google Scholar : PubMed/NCBI
21	LeBel CP, Ischiropoulos H and Bondy SC: Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol. 5:227–231. 1992. View Article : Google Scholar : PubMed/NCBI
22	Wei J, Liu Y, Chang M, Sun CL, Li DW, Liu ZQ and Hu LS: Proteomic analysis of oxidative modification in endothelial colony-forming cells treated by hydrogen peroxide. Int J Mol Med. 29:1099–1105. 2012.PubMed/NCBI
23	Decaris ML, Lee CI, Yoder MC, Tarantal AF and Leach JK: Influence of the oxygen microenvironment on the proangiogenic potential of human endothelial colony forming cells. Angiogenesis. 12:303–311. 2009. View Article : Google Scholar : PubMed/NCBI
24	Baskić D, Popović S, Ristić P and Arsenijević NN: Analysis of cycloheximide-induced apoptosis in human leukocytes: Fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide. Cell Biol Int. 30:924–932. 2006. View Article : Google Scholar
25	Li DW, Yao M, Dong YH, Tang MN, Chen W, Li GR and Sun BQ: Guanosine exerts neuroprotective effects by reversing mitochondrial dysfunction in a cellular model of Parkinson's disease. Int J Mol Med. 34:1358–1364. 2014.PubMed/NCBI
26	Ingram DA, Krier TR, Mead LE, McGuire C, Prater DN, Bhavsar J, Saadatzadeh MR, Bijangi-Vishehsaraei K, Li F, Yoder MC and Haneline LS: Clonogenic endothelial progenitor cells are sensitive to oxidative stress. Stem Cells. 25:297–304. 2007. View Article : Google Scholar
27	Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, et al: Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA. 77:3957–3961. 1980. View Article : Google Scholar : PubMed/NCBI
28	Istvan ES and Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 292:1160–1164. 2001. View Article : Google Scholar : PubMed/NCBI
29	Laufs U, La Fata V, Plutzky J and Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1129–1135. 1998. View Article : Google Scholar : PubMed/NCBI
30	Liao JK and Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 45:89–118. 2005. View Article : Google Scholar : PubMed/NCBI
31	Chiang Y, Rizzino A, Sibenaller ZA, Wold MS and Vishwanatha JK: Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol Cell Biochem. 199:139–147. 1999. View Article : Google Scholar : PubMed/NCBI
32	Emans N, Gorvel JP, Walter C, Gerke V, Kellner R, Griffiths G and Gruenberg J: Annexin II is a major component of fusogenic endosomal vesicles. J Cell Biol. 120:1357–1369. 1993. View Article : Google Scholar : PubMed/NCBI
33	Sarafian T, Pradel LA, Henry JP, Aunis D and Bader MF: The participation of annexin II (calpactin I) in calcium-evoked exocytosis requires protein kinase C. J Cell Biol. 114:1135–1147. 1991. View Article : Google Scholar : PubMed/NCBI
34	Oliferenko S, Paiha K, Harder T, Gerke V, Schwärzler C, Schwarz H, Beug H, Günthert U and Huber LA: Analysis of CD44-containing lipid rafts: Recruitment of annexin II and stabilization by the actin cytoskeleton. J Cell Biol. 146:843–854. 1999. View Article : Google Scholar : PubMed/NCBI
35	Huang Y, Jin Y, Yan CH, Yu Y, Bai J, Chen F, Zhao YZ and Fu SB: Involvement of Annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem. 309:117–123. 2008. View Article : Google Scholar
36	Rand JH: The annexinopathies: A new category of diseases. Biochim Biophys Acta. 1498:169–173. 2000. View Article : Google Scholar : PubMed/NCBI
37	Hayes MJ, Longbottom RE, Evans MA and Moss SE: Annexinopathies. Subcell Biochem. 45:1–28. 2007. View Article : Google Scholar
38	Gerke V and Weber K: The regulatory chain in the p36-kd substrate complex of viral tyrosine-specific protein kinases is related in sequence to the S-100 protein of glial cells. EMBO J. 4:2917–2920. 1985.PubMed/NCBI
39	Waisman DM: Annexin II tetramer: Structure and function. Mol Cell Biochem. 149–150:301–322. 1995. View Article : Google Scholar
40	Zokas L and Glenney JR Jr: The calpactin light chain is tightly linked to the cytoskeletal form of calpactin I: Studies using monoclonal antibodies to calpactin subunits. J Cell Biol. 105:2111–2121. 1987. View Article : Google Scholar : PubMed/NCBI
41	Madureira PA, Hill R, Miller VA, Giacomantonio C, Lee PW and Waisman DM: Annexin A2 is a novel cellular redox regulatory protein involved in tumorigenesis. Oncotarget. 2:1075–1093. 2011. View Article : Google Scholar : PubMed/NCBI
42	Cesarman GM, Guevara CA and Hajjar KA: An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem. 269:21198–21203. 1994.PubMed/NCBI
43	Sharma M, Ownbey RT and Sharma MC: Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol. 88:278–286. 2010. View Article : Google Scholar : PubMed/NCBI
44	Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med. 6:389–395. 2000. View Article : Google Scholar : PubMed/NCBI
45	Raddum AM, Evensen L, Hollås H, Grindheim AK, Lorens JB and Vedeler A: Domains I and IV of annexin A2 affect the formation and integrity of in vitro capillary-like networks. PLoS One. 8:e602812013. View Article : Google Scholar : PubMed/NCBI
46	Dejana E, Orsenigo F and Lampugnani MG: The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci. 121:2115–2122. 2008. View Article : Google Scholar : PubMed/NCBI
47	Pollard TD and Borisy GG: Cellular motility driven by assembly and disassembly of actin filaments. Cell. 112:453–465. 2003. View Article : Google Scholar : PubMed/NCBI
48	Revenu C, Athman R, Robine S and Louvard D: The co-workers of actin filaments: From cell structures to signals. Nat Rev Mol Cell Biol. 5:635–646. 2004. View Article : Google Scholar : PubMed/NCBI
49	Zhang X, Cui X, Cheng L, Guan X, Li H, Li X and Cheng M: Actin stabilization by jasplakinolide affects the function of bone marrow-derived late endothelial progenitor cells. PLoS One. 7:e508992012. View Article : Google Scholar : PubMed/NCBI
50	Hayes MJ, Shao D, Bailly M and Moss SE: Regulation of actin dynamics by annexin 2. EMBO J. 25:1816–1826. 2006. View Article : Google Scholar : PubMed/NCBI
51	Yu HY, Inoguchi T, Nakayama M, Tsubouchi H, Sato N, Sonoda N, Sasaki S, Kobayashi K and Nawata H: Statin attenuates high glucose-induced and angiotensin II-induced MAP kinase activity through inhibition of NAD(P)H oxidase activity in cultured mesangial cells. Med Chem. 1:461–466. 2005. View Article : Google Scholar
52	Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC and Walsh K: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 6:1004–1010. 2000. View Article : Google Scholar : PubMed/NCBI
53	Wang CY, Lin YS, Su WC, Chen CL and Lin CF: Glycogen synthase kinase-3 and Omi/HtrA2 induce annexin A2 cleavage followed by cell cycle inhibition and apoptosis. Mol Biol Cell. 20:4153–4161. 2009. View Article : Google Scholar : PubMed/NCBI